Lung Cancer Trial, Recruiting NCT06295497 Sponsor: Chinese University of Hong Kong Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT06295497
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 50 and 75 years old
  • People who have smoked fewer than 100 cigarettes in their entire lifetime (considered a non-smoker for this trial)
  • People who have a parent, sibling, or child who has been diagnosed with lung cancer
  • People who are healthy enough to receive curative (aimed at curing) treatment if an early-stage lung cancer were to be found
  • People who are willing and able to sign a written consent form
  • People who agree to attend follow-up visits and have a follow-up CT scan if the trial team recommends one
  • People who agree to have blood taken for research purposes

Who may not be able to join:

  • People who have a history of any cancer
  • People who have smoked more than 100 cigarettes in their lifetime
  • People who currently have symptoms that could suggest lung cancer, such as coughing up blood, chest pain, or unexplained weight loss
  • People with serious health conditions that would prevent them from having surgery, such as severe heart disease, serious breathing problems, a need for home oxygen, or a bleeding disorder
  • People who are pregnant or planning to become pregnant
  • People with a history of tuberculosis (TB) or scarring/inflammation of the lungs (interstitial lung disease)
  • People who have had a lung infection requiring antibiotics in the past 12 weeks
  • People who have had a chest CT scan, PET-CT, or chest MRI within the past 2 years, or whose previous scan raised concerns about lung cancer
  • People who are unable or unwilling to sign a written consent form

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 3505 2166

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
18 July 2024
Est. completion
1 September 2028

Where this trial is recruiting

Hong Kong

Primary endpoints

Sensitivity, specificity, positive predictive value and negative predictive value of AI-assisted programme in lung nodule (≥5mm) detection and monitoring compared to radiologist assessment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov